Croda International reported first-quarter sales of £431 million on Wednesday, showing a 2% decline compared with the same period a year ago but a 1% increase on a constant currency basis. The overall top line came in slightly below market expectations, reflecting softness in its Life Sciences operations.
Quarterly headline and market reaction
The group's reported sales figure was 2% under the consensus estimate of £442 million. Company commentary identified Life Sciences as the primary area of underperformance versus analysts' forecasts.
Performance by division
- Consumer Care - Sales in the Consumer Care segment reached £255 million. This was flat year-over-year on a reported basis and recorded a 4% increase on a constant currency basis. Within this segment, Beauty Actives expanded across all regions, supported by a renewed appetite for innovation and continued spending among higher-income households. Fragrance & Flavours delivered strong growth, rising 10% on a constant currency basis despite Croda's 20% exposure to the Middle East. Home Care also recovered from a weaker fourth quarter, posting 6% growth.
- Life Sciences - Sales in Life Sciences were £126 million, down 6% year-over-year and down 3% on a constant currency basis. The division missed analyst expectations by 8%. The decline was attributed in part to a tough comparison in Crop Protection, which benefited from restocking in the prior year, and to weakness in Pharma. Seed Enhancement was the more resilient area within the division, showing 2% growth on a constant currency basis.
- Industrial Specialties - This division reported sales of £50 million, a 5% decline year-over-year and a 2% decrease on a constant currency basis.
Regional trends
On a regional basis, Croda said sales increased 2% in constant currency in EMEA and 2% in Asia. Latin America recorded stronger expansion with an 11% improvement, while North America saw a 7% decline.
Outlook and guidance
Croda reiterated its full-year guidance, continuing to target 3% to 6% organic sales growth. The company also confirmed that adjusted operating profit is expected to be in line with current market expectations of £322 million at constant currency. Management noted that the Middle East did not have any material effect on results in the first quarter.
Implications
The quarter left the group broadly on track with its stated annual targets despite the shortfall versus consensus and the mixed performance across divisions and regions. The Life Sciences downturn, particularly versus a prior period that included restocking, was the principal driver of the miss against analyst expectations.